Vebicorvir (ABI-H0731) is a first-generation inhibitor of HBV (hepatitis B virus) core protein. Vebicorvir (ABI-H0731) covalently inhibits cccDNA in two infection models with EC50s of 1.84-7.3 μM.

Physicochemical Properties

Molecular Formula	C19H12F3N3O4S2
Molecular Weight	467.441492080688
Exact Mass	467.022
CAS #	2090064-66-5
PubChem CID	139394142
Appearance	White to off-white solid powder
Density	1.6±0.1 g/cm3
Boiling Point	566.3±50.0 °C at 760 mmHg
Flash Point	296.3±30.1 °C
Vapour Pressure	0.0±1.5 mmHg at 25°C
Index of Refraction	1.619
LogP	2.02
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	3
Heavy Atom Count	31
Complexity	817
Defined Atom Stereocenter Count	0
InChi Key	LBJVBJYMZKEREY-UHFFFAOYSA-N
InChi Code	InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27)
Chemical Name	11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide
Synonyms	ABI H0731 ABI-H0731 ABIH0731 ABIH 0731 ABIH-0731 ABI H 0731 ABI H-0731
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis [1]. It can suppress the production of pgRNA, HBeAg, and HBsAg with EC50 of 2.68 μM, 4.95 μM, and 7.30 μM, respectively.
ln Vivo	After intravenous administration, the medication was rapidly disseminated and degraded in a biphasic way in all species examined. The plasma clearance rates of ABI-H0731 are 8.05, 10.1, 14.7 and 4.86 ml/min/kg, representing 9%, 16%, 47% and 11% of hepatic blood flow in mice, rats, dogs and monkeys, respectively[1] .
References	[1]. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~213.93 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.1393 mL	10.6966 mL	21.3931 mL
	5 mM	0.4279 mL	2.1393 mL	4.2786 mL
	10 mM	0.2139 mL	1.0697 mL	2.1393 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.